| Literature DB >> 34847884 |
Xi Xie1, Xiangjie Fu1, Yawen Zhang1, Wanting Huang1, Lingjin Huang2, Ying Deng3, Danyang Yan1, Run Yao4, Ning Li5.
Abstract
BACKGROUND: The platelet-lymphocyte ratio (PLR), a novel inflammatory marker, is generally associated with increased in-hospital mortality risk. We aimed to investigate the association between PLR and postoperative in-hospital mortality risk in patients with type A acute aortic dissection (AAAD).Entities:
Keywords: In-hospital mortality; Platelet–lymphocyte ratio; Type A acute aortic dissection
Mesh:
Year: 2021 PMID: 34847884 PMCID: PMC8638137 DOI: 10.1186/s12872-021-02391-x
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Baseline characteristics of patients by PLR tertiles
| Variables | PLR tertiles | |||
|---|---|---|---|---|
| T1 (< 112.73) | T2 (112.73–179) | T3 (> 179) | ||
| Age (year) | 50.93 ± 10.72 | 49.52 ± 11.65 | 49.52 ± 11.02 | 0.618 |
| Sex (male) | 69 (76.67%) | 57 (63.33%) | 63 (70.00%) | 0.149 |
| Lymphocyte (109/L) | 1.50 (1.20–2.20) | 1.20 (1.00–1.40) | 0.70 (0.60–1.00) | < 0.001* |
| Platelet count (109/L) | 127.50 (95–150.75) | 174 (147.50–215.25) | 181 (148.25–232.75) | < 0.001* |
| Hemoglobin (g/L) | 121.70 ± 21.11 | 122.82 ± 19.07 | 121.01 ± 22.10 | 0.840 |
| INR | 1.11 (1.04–1.24) | 1.09 (1.01–1.17) | 1.10 (1.04–1.17) | 0.501 |
| PT (s) | 14.05 (13.22–15.45) | 13.80 (12.93–14.70) | 14.00 (13.30–14.90) | 0.115 |
| APTT (s) | 35.60 (31.85–38.98) | 33.55 (29.65–37.95) | 33.65 (30.70–37.25) | 0.389 |
| Smoking | 44 (48.89%) | 36 (40.00%) | 43 (47.78%) | 0.427 |
| Alcohol consumption | 31 (34.44%) | 32 (35.56%) | 33 (36.67%) | 0.953 |
| Hypertension | 65 (72.22%) | 60 (66.67%) | 62 (68.89%) | 0.719 |
| Diabetes mellitus | 3 (3.33%) | 6 (6.67%) | 4 (4.44%) | 0.568 |
| Marfan syndrome | 3 (3.33%) | 10 (11.11%) | 4 (4.44%) | 0.067 |
| Hemopericardium | 9 (10.00%) | 6 (6.67%) | 10 (11.11%) | 0.564 |
| Coronary artery disease | 10 (11.11%) | 7 (7.78%) | 6 (6.67%) | 0.539 |
| Cerebrovascular disease | 4 (4.44%) | 4 (4.44%) | 6 (6.67%) | 0.740 |
| Chronic renal failure | 5 (5.56%) | 3 (3.33%) | 4 (4.44%) | 0.770 |
| Penn class | 0.479 | |||
| Class Aa | 55 (61.11%) | 48 (53.33%) | 48 (53.33%) | |
| Non class Aa | 35 (38.89%) | 42 (46.67%) | 42 (46.67%) | |
| CPB time (min) | 176 (146–207.25) | 174.5 (143.5–202.75) | 176 (144.25–197) | 0.424 |
| Ventilator use | 51 (56.67%) | 46 (51.11%) | 51 (56.67%) | 0.688 |
| Operative time (hour) | 11 (9–12) | 10 (9–11.75) | 10 (8–12) | 0.344 |
| Surgery type | 0.055 | |||
| AAR + TAR (TAVR) + FET | 42 (46.67%) | 49 (54.44%) | 42 (46.67%) | |
| Bentall + TAR (TAVR) + FET | 27 (30.00%) | 16 (17.78%) | 15 (16.67%) | |
| David + TAVR + FET | 1 (1.11%) | 6 (6.67%) | 3 (3.33%) | |
| Combine others | 20 (22.22%) | 19 (21.11%) | 30 (33.33%) | |
| Autologous blood transfusion (≥ 500 ml) | 20 (22.22%) | 31 (34.44%) | 32 (35.56%) | 0.099 |
| Platelet (therapeutic dose) | 0.003* | |||
| ≤ 1 | 44 (48.89%) | 53 (58.89%) | 66 (73.33%) | |
| > 1 | 46 (51.11%) | 37 (41.11%) | 24 (26.67%) | |
| Cryoprecipitate (therapeutic dose) | 0.456 | |||
| ≤ 1 | 53 (58.89%) | 58 (64.44%) | 61 (67.78%) | |
| > 1 | 37 (41.11%) | 32 (35.56%) | 29 (32.22%) | |
| RBCs (unit) | 0.438 | |||
| ≤ 10 | 57 (63.33%) | 60 (66.67%) | 65 (72.22%) | |
| > 10 | 33 (36.67%) | 30 (33.33%) | 25 (27.78%) | |
| Plasma (unit) | 0.099 | |||
| ≤ 10 | 38 (42.22%) | 52 (57.78%) | 48 (53.33%) | |
| > 10 | 52 (57.78%) | 38 (42.22%) | 42 (46.67%) | |
| Postoperative in-hospital mortality | 21 (23.33%) | 6 (6.67%) | 9 (10.00%) | 0.002* |
Results are expressed as mean ± SD, median (Q1-Q3) or n (%). *, P < 0.05. PLR, platelet-lymphocyte ratio; INR, international normalized ratio; PT, prothrombin time; APTT, activated partial thromboplastin time; CPB, cardiopulmonary bypass; AAR, ascending aorta replacement; TAR, total arch replacement; TAVR, total aortic vascular replacement; FET, frozen elephant trunk; RBCs, red blood cells
Fig. 1Univariate analysis. Odds ratios and P values are presented to show the association between the variables and postoperative in-hospital mortality in patients with AAAD
Multivariable regressions analysis in different models
| Variables | Model I | Model II | Model III | Model IV |
|---|---|---|---|---|
| PLR | 0.99 (0.99, 1.00)* | 0.99 (0.99, 1.00) * | 0.99 (0.99, 1.00) | 0.99 (0.99, 1.00) |
| PLR tertiles | ||||
| T1 | Ref | Ref | Ref | Ref |
| T2 | 0.30 (0.12, 0.75)* | 0.31 (0.12, 0.78) * | 0.17 (0.05, 0.58) * | 0.20 (0.06, 0.66) * |
| T3 | 0.34 (0.14, 0.82)* | 0.36 (0.15, 0.87) * | 0.32 (0.10, 0.97) * | 0.30 (0.09, 0.92) * |
| 0.01 | 0.01 | 0.02 | 0.02 | |
*P < 0.05. OR, odds ratio; CI, confidence interval; Ref, reference. Model I, adjusted for none; Model II, adjusted for age and sex; Model III, adjusted for age, sex, cerebrovascular disease, chronic renal failure, autologous blood (≥ 500 ml), cryoprecipitate, RBCs, plasma, platelet, surgery type, Marfan syndrome, operative time; Model IV, adjusted for age, sex, alcohol consumption, diabetes mellitus, cerebrovascular disease, chronic renal failure, autologous blood (≥ 500 ml), cryoprecipitate, RBCs, plasma, platelet, operative time
Fig. 2Smoothing spline fitting curve. After adjusting for age; sex; cerebrovascular disease; chronic renal failure; autologous blood (≥ 500 mL), cryoprecipitate, RBCs, plasma, and platelet transfusion; surgery type; Marfan syndrome; and operative time, we observed a U-shaped relationship between PLR and postoperative in-hospital mortality risk in patients with AAAD. Nonlinear plots are displayed with red dotted lines, and the blue dotted lines represent 95% confidence intervals
Threshold effect analysis
| Models | Adjusted OR (95%CI) | |
|---|---|---|
| Model I | ||
| One line slope | 1.00 (0.99, 1.01) | 0.351 |
| Model II | ||
| Turning point (K1, K2) | 108, 188 | |
| < 108 slope 1 | 0.90 (0.85, 0.96) | 0.001 |
| 108–188 slope 2 | 1.02 (0.98, 1.05) | 0.288 |
| > 188 slope 3 | 1.06 (1.00, 1.13) | 0.045 |
| LRT test | < 0.001# | |
Data are presented as OR (95% CI) and P-value; # indicates that model II is significant different from model I
Model I, linear analysis; model II, nonlinear analysis. LRT, Logarithmic likelihood ratio test. (P < 0.05 means model II is significantly different from model I, which indicates a nonlinear relationship). All adjusted for age, sex, cerebrovascular disease, chronic renal failure, autologous blood (≥ 500 ml), cryoprecipitate, RBCs, plasma, platelet, surgery type, Marfan syndrome, operative time